nodes	percent_of_prediction	percent_of_DWPC	metapath
Omeprazole—kidney cancer—Hydrocortisone—psoriasis	0.128	0.261	CpDpCtD
Omeprazole—prostate cancer—Hydrocortisone—psoriasis	0.0927	0.189	CpDpCtD
Omeprazole—kidney cancer—Dexamethasone—psoriasis	0.0783	0.16	CpDpCtD
Omeprazole—kidney cancer—Betamethasone—psoriasis	0.0783	0.16	CpDpCtD
Omeprazole—prostate cancer—Dexamethasone—psoriasis	0.0566	0.115	CpDpCtD
Omeprazole—prostate cancer—Betamethasone—psoriasis	0.0566	0.115	CpDpCtD
Omeprazole—CYP11A1—Cholecalciferol—psoriasis	0.0464	0.125	CbGbCtD
Omeprazole—CYP1A1—Clobetasol propionate—psoriasis	0.0336	0.0905	CbGbCtD
Omeprazole—ABCC3—Cyclosporine—psoriasis	0.0203	0.0545	CbGbCtD
Omeprazole—CYP11A1—Dexamethasone—psoriasis	0.0201	0.0541	CbGbCtD
Omeprazole—CYP1A1—Methoxsalen—psoriasis	0.0177	0.0475	CbGbCtD
Omeprazole—CYP2C8—Tazarotene—psoriasis	0.0158	0.0426	CbGbCtD
Omeprazole—CYP1A2—Clobetasol propionate—psoriasis	0.015	0.0404	CbGbCtD
Omeprazole—CYP1A1—Cholecalciferol—psoriasis	0.0117	0.0315	CbGbCtD
Omeprazole—CYP1B1—Dexamethasone—psoriasis	0.0115	0.031	CbGbCtD
Omeprazole—ABCG2—Mycophenolate mofetil—psoriasis	0.011	0.0296	CbGbCtD
Omeprazole—ABCC3—Methotrexate—psoriasis	0.0107	0.0289	CbGbCtD
Omeprazole—ABCG2—Hydrocortisone—psoriasis	0.00882	0.0237	CbGbCtD
Omeprazole—ABCG2—Cyclosporine—psoriasis	0.00833	0.0224	CbGbCtD
Omeprazole—CYP1A2—Methoxsalen—psoriasis	0.00789	0.0212	CbGbCtD
Omeprazole—CYP2D6—Hydroxyurea—psoriasis	0.00711	0.0191	CbGbCtD
Omeprazole—CYP2C8—Cholecalciferol—psoriasis	0.00675	0.0182	CbGbCtD
Omeprazole—CYP2C8—Mycophenolate mofetil—psoriasis	0.00586	0.0158	CbGbCtD
Omeprazole—CYP2C19—Cholecalciferol—psoriasis	0.00567	0.0152	CbGbCtD
Omeprazole—ABCG2—Dexamethasone—psoriasis	0.00549	0.0148	CbGbCtD
Omeprazole—CYP3A4—Calcitriol—psoriasis	0.00532	0.0143	CbGbCtD
Omeprazole—CYP1A1—Dexamethasone—psoriasis	0.00506	0.0136	CbGbCtD
Omeprazole—CYP2C9—Cholecalciferol—psoriasis	0.00471	0.0127	CbGbCtD
Omeprazole—CYP2C8—Hydrocortisone—psoriasis	0.0047	0.0126	CbGbCtD
Omeprazole—CYP2C8—Cyclosporine—psoriasis	0.00444	0.0119	CbGbCtD
Omeprazole—ABCG2—Methotrexate—psoriasis	0.00441	0.0119	CbGbCtD
Omeprazole—CYP2D6—Cholecalciferol—psoriasis	0.00431	0.0116	CbGbCtD
Omeprazole—CYP3A4—Methoxsalen—psoriasis	0.00413	0.0111	CbGbCtD
Omeprazole—ABCB1—Mycophenolate mofetil—psoriasis	0.00396	0.0107	CbGbCtD
Omeprazole—CYP2C19—Prednisone—psoriasis	0.00393	0.0106	CbGbCtD
Omeprazole—CYP2C19—Cyclosporine—psoriasis	0.00372	0.01	CbGbCtD
Omeprazole—ABCB1—Betamethasone—psoriasis	0.0034	0.00915	CbGbCtD
Omeprazole—ABCB1—Prednisolone—psoriasis	0.00336	0.00903	CbGbCtD
Omeprazole—ABCB1—Hydrocortisone—psoriasis	0.00318	0.00856	CbGbCtD
Omeprazole—ABCB1—Prednisone—psoriasis	0.00317	0.00852	CbGbCtD
Omeprazole—CYP2C9—Cyclosporine—psoriasis	0.0031	0.00833	CbGbCtD
Omeprazole—ABCB1—Cyclosporine—psoriasis	0.003	0.00808	CbGbCtD
Omeprazole—CYP2C8—Dexamethasone—psoriasis	0.00292	0.00786	CbGbCtD
Omeprazole—CYP2D6—Cyclosporine—psoriasis	0.00283	0.00761	CbGbCtD
Omeprazole—CYP3A4—Cholecalciferol—psoriasis	0.00274	0.00737	CbGbCtD
Omeprazole—CYP2C19—Dexamethasone—psoriasis	0.00245	0.0066	CbGbCtD
Omeprazole—CYP3A4—Mycophenolate mofetil—psoriasis	0.00237	0.00639	CbGbCtD
Omeprazole—CYP3A4—Triamcinolone—psoriasis	0.00237	0.00639	CbGbCtD
Omeprazole—CYP2C9—Dexamethasone—psoriasis	0.00204	0.00548	CbGbCtD
Omeprazole—CYP3A4—Betamethasone—psoriasis	0.00204	0.00548	CbGbCtD
Omeprazole—CYP3A4—Prednisolone—psoriasis	0.00201	0.00541	CbGbCtD
Omeprazole—ABCB1—Dexamethasone—psoriasis	0.00198	0.00532	CbGbCtD
Omeprazole—CYP3A4—Hydrocortisone—psoriasis	0.00191	0.00513	CbGbCtD
Omeprazole—CYP3A4—Prednisone—psoriasis	0.0019	0.00511	CbGbCtD
Omeprazole—CYP2D6—Dexamethasone—psoriasis	0.00186	0.00501	CbGbCtD
Omeprazole—CYP3A4—Cyclosporine—psoriasis	0.0018	0.00484	CbGbCtD
Omeprazole—ABCB1—Methotrexate—psoriasis	0.00159	0.00428	CbGbCtD
Omeprazole—CYP3A4—Dexamethasone—psoriasis	0.00119	0.00319	CbGbCtD
Omeprazole—CYP2C18—Biological oxidations—CYP2S1—psoriasis	0.000189	0.00794	CbGpPWpGaD
Omeprazole—CYP2C18—Metapathway biotransformation—CYP2S1—psoriasis	0.000186	0.00783	CbGpPWpGaD
Omeprazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000182	0.00768	CbGpPWpGaD
Omeprazole—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00018	0.00758	CbGpPWpGaD
Omeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000163	0.00685	CbGpPWpGaD
Omeprazole—CYP2C18—Tryptophan metabolism—CAT—psoriasis	0.000163	0.00685	CbGpPWpGaD
Omeprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000161	0.00679	CbGpPWpGaD
Omeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000161	0.00676	CbGpPWpGaD
Omeprazole—CYP1B1—Estrogen Receptor Pathway—JUN—psoriasis	0.000158	0.00666	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000155	0.00652	CbGpPWpGaD
Omeprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00015	0.0063	CbGpPWpGaD
Omeprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000149	0.00625	CbGpPWpGaD
Omeprazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000148	0.00622	CbGpPWpGaD
Omeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000148	0.00622	CbGpPWpGaD
Omeprazole—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000147	0.00617	CbGpPWpGaD
Omeprazole—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000139	0.00587	CbGpPWpGaD
Omeprazole—CYP1B1—Biological oxidations—CYP2S1—psoriasis	0.000139	0.00586	CbGpPWpGaD
Omeprazole—CYP1B1—Metapathway biotransformation—CYP2S1—psoriasis	0.000137	0.00577	CbGpPWpGaD
Omeprazole—CYP1B1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000137	0.00576	CbGpPWpGaD
Omeprazole—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000137	0.00575	CbGpPWpGaD
Omeprazole—CYP1B1—Melatonin metabolism and effects—APOE—psoriasis	0.000135	0.00568	CbGpPWpGaD
Omeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000132	0.00555	CbGpPWpGaD
Omeprazole—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000127	0.00535	CbGpPWpGaD
Omeprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000127	0.00534	CbGpPWpGaD
Omeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000125	0.00527	CbGpPWpGaD
Omeprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000121	0.00511	CbGpPWpGaD
Omeprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00012	0.00506	CbGpPWpGaD
Omeprazole—CYP1B1—Tryptophan metabolism—CAT—psoriasis	0.00012	0.00505	CbGpPWpGaD
Omeprazole—ATP4B—Transmembrane transport of small molecules—CP—psoriasis	0.000114	0.00479	CbGpPWpGaD
Omeprazole—ATP4B—Transmembrane transport of small molecules—CARM1—psoriasis	0.000109	0.00457	CbGpPWpGaD
Omeprazole—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000104	0.00438	CbGpPWpGaD
Omeprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000103	0.00433	CbGpPWpGaD
Omeprazole—ABCC3—NRF2 pathway—TGFA—psoriasis	0.000102	0.0043	CbGpPWpGaD
Omeprazole—ATP4A—Transmembrane transport of small molecules—CP—psoriasis	0.000101	0.00427	CbGpPWpGaD
Omeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	9.79e-05	0.00412	CbGpPWpGaD
Omeprazole—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	9.75e-05	0.0041	CbGpPWpGaD
Omeprazole—ATP4A—Transmembrane transport of small molecules—CARM1—psoriasis	9.67e-05	0.00407	CbGpPWpGaD
Omeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	9.67e-05	0.00407	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	9.55e-05	0.00402	CbGpPWpGaD
Omeprazole—CYP1A1—Biological oxidations—CYP2S1—psoriasis	8.57e-05	0.00361	CbGpPWpGaD
Omeprazole—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	8.45e-05	0.00356	CbGpPWpGaD
Omeprazole—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	8.44e-05	0.00355	CbGpPWpGaD
Omeprazole—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	8.31e-05	0.0035	CbGpPWpGaD
Omeprazole—CYP2C18—FOXA1 transcription factor network—JUN—psoriasis	8.1e-05	0.00341	CbGpPWpGaD
Omeprazole—CYP1B1—Melatonin metabolism and effects—NFKB1—psoriasis	8.02e-05	0.00338	CbGpPWpGaD
Omeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.94e-05	0.00334	CbGpPWpGaD
Omeprazole—CYP2C8—Biological oxidations—CYP2S1—psoriasis	7.86e-05	0.00331	CbGpPWpGaD
Omeprazole—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	7.83e-05	0.0033	CbGpPWpGaD
Omeprazole—CYP11A1—Corticotropin-releasing hormone—NFKBIA—psoriasis	7.83e-05	0.00329	CbGpPWpGaD
Omeprazole—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	7.75e-05	0.00326	CbGpPWpGaD
Omeprazole—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	7.54e-05	0.00317	CbGpPWpGaD
Omeprazole—CYP1A1—Tryptophan metabolism—CAT—psoriasis	7.39e-05	0.00311	CbGpPWpGaD
Omeprazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.3e-05	0.00307	CbGpPWpGaD
Omeprazole—CYP2C19—Biological oxidations—CYP2S1—psoriasis	7.01e-05	0.00295	CbGpPWpGaD
Omeprazole—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	6.92e-05	0.00291	CbGpPWpGaD
Omeprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.82e-05	0.00287	CbGpPWpGaD
Omeprazole—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	6.8e-05	0.00286	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.67e-05	0.00281	CbGpPWpGaD
Omeprazole—ABCC3—Fluoropyrimidine Activity—TP53—psoriasis	6.55e-05	0.00275	CbGpPWpGaD
Omeprazole—CYP2D6—Biological oxidations—CYP2S1—psoriasis	6.45e-05	0.00271	CbGpPWpGaD
Omeprazole—CYP2C9—Biological oxidations—CYP2S1—psoriasis	6.39e-05	0.00269	CbGpPWpGaD
Omeprazole—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	6.36e-05	0.00268	CbGpPWpGaD
Omeprazole—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	6.36e-05	0.00268	CbGpPWpGaD
Omeprazole—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	6.31e-05	0.00265	CbGpPWpGaD
Omeprazole—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	6.25e-05	0.00263	CbGpPWpGaD
Omeprazole—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	6.22e-05	0.00262	CbGpPWpGaD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	6.09e-05	0.00256	CbGpPWpGaD
Omeprazole—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	5.98e-05	0.00252	CbGpPWpGaD
Omeprazole—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.93e-05	0.00249	CbGpPWpGaD
Omeprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	5.86e-05	0.00246	CbGpPWpGaD
Omeprazole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	5.83e-05	0.00245	CbGpPWpGaD
Omeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.83e-05	0.00245	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—HLA-C—psoriasis	5.82e-05	0.00245	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—IL13—psoriasis	5.78e-05	0.00243	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.76e-05	0.00242	CbGpPWpGaD
Omeprazole—CYP11A1—Corticotropin-releasing hormone—CXCL8—psoriasis	5.58e-05	0.00235	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.55e-05	0.00233	CbGpPWpGaD
Omeprazole—CYP1A2—Biological oxidations—CYP2S1—psoriasis	5.46e-05	0.0023	CbGpPWpGaD
Omeprazole—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	5.39e-05	0.00227	CbGpPWpGaD
Omeprazole—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	5.38e-05	0.00226	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—IL17A—psoriasis	5.32e-05	0.00224	CbGpPWpGaD
Omeprazole—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	5.3e-05	0.00223	CbGpPWpGaD
Omeprazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.09e-05	0.00214	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.04e-05	0.00212	CbGpPWpGaD
Omeprazole—CYP11A1—Corticotropin-releasing hormone—NFKB1—psoriasis	5e-05	0.0021	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—IL12B—psoriasis	4.95e-05	0.00208	CbGpPWpGaD
Omeprazole—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	4.94e-05	0.00208	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—HLA-E—psoriasis	4.83e-05	0.00203	CbGpPWpGaD
Omeprazole—CYP1A1—Oxidative Stress—NFKB1—psoriasis	4.81e-05	0.00202	CbGpPWpGaD
Omeprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.76e-05	0.002	CbGpPWpGaD
Omeprazole—CYP1A2—Tryptophan metabolism—CAT—psoriasis	4.71e-05	0.00198	CbGpPWpGaD
Omeprazole—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	4.51e-05	0.0019	CbGpPWpGaD
Omeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.5e-05	0.00189	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—NDUFA5—psoriasis	4.39e-05	0.00185	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.32e-05	0.00182	CbGpPWpGaD
Omeprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.32e-05	0.00182	CbGpPWpGaD
Omeprazole—CYP3A4—Biological oxidations—CYP2S1—psoriasis	4.22e-05	0.00177	CbGpPWpGaD
Omeprazole—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	4.16e-05	0.00175	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.11e-05	0.00173	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.09e-05	0.00172	CbGpPWpGaD
Omeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.06e-05	0.00171	CbGpPWpGaD
Omeprazole—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	4.04e-05	0.0017	CbGpPWpGaD
Omeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	4.04e-05	0.0017	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	4e-05	0.00168	CbGpPWpGaD
Omeprazole—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	3.93e-05	0.00165	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—NDUFA5—psoriasis	3.8e-05	0.0016	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—CYP2S1—psoriasis	3.73e-05	0.00157	CbGpPWpGaD
Omeprazole—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	3.72e-05	0.00156	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—NDUFA5—psoriasis	3.69e-05	0.00155	CbGpPWpGaD
Omeprazole—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.64e-05	0.00153	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—IL10—psoriasis	3.62e-05	0.00152	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.55e-05	0.00149	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—IL4—psoriasis	3.52e-05	0.00148	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.44e-05	0.00145	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—HLA-B—psoriasis	3.44e-05	0.00145	CbGpPWpGaD
Omeprazole—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	3.44e-05	0.00145	CbGpPWpGaD
Omeprazole—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	3.43e-05	0.00144	CbGpPWpGaD
Omeprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.43e-05	0.00144	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.42e-05	0.00144	CbGpPWpGaD
Omeprazole—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	3.27e-05	0.00138	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—CYP2S1—psoriasis	3.23e-05	0.00136	CbGpPWpGaD
Omeprazole—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.2e-05	0.00135	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.19e-05	0.00134	CbGpPWpGaD
Omeprazole—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	3.15e-05	0.00133	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—CYP2S1—psoriasis	3.14e-05	0.00132	CbGpPWpGaD
Omeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.14e-05	0.00132	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.1e-05	0.0013	CbGpPWpGaD
Omeprazole—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	2.92e-05	0.000256	CcSEcCtD
Omeprazole—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.91e-05	0.00123	CbGpPWpGaD
Omeprazole—Urticaria—Cyclosporine—psoriasis	2.91e-05	0.000255	CcSEcCtD
Omeprazole—Myalgia—Betamethasone—psoriasis	2.9e-05	0.000255	CcSEcCtD
Omeprazole—Myalgia—Dexamethasone—psoriasis	2.9e-05	0.000255	CcSEcCtD
Omeprazole—Abdominal pain—Cyclosporine—psoriasis	2.89e-05	0.000254	CcSEcCtD
Omeprazole—Body temperature increased—Cyclosporine—psoriasis	2.89e-05	0.000254	CcSEcCtD
Omeprazole—Anxiety—Dexamethasone—psoriasis	2.89e-05	0.000254	CcSEcCtD
Omeprazole—Anxiety—Betamethasone—psoriasis	2.89e-05	0.000254	CcSEcCtD
Omeprazole—Vomiting—Mycophenolic acid—psoriasis	2.88e-05	0.000253	CcSEcCtD
Omeprazole—Discomfort—Betamethasone—psoriasis	2.87e-05	0.000251	CcSEcCtD
Omeprazole—Discomfort—Dexamethasone—psoriasis	2.87e-05	0.000251	CcSEcCtD
Omeprazole—Dyspepsia—Hydrocortisone—psoriasis	2.86e-05	0.000251	CcSEcCtD
Omeprazole—Rash—Mycophenolic acid—psoriasis	2.85e-05	0.00025	CcSEcCtD
Omeprazole—Dermatitis—Mycophenolic acid—psoriasis	2.85e-05	0.00025	CcSEcCtD
Omeprazole—Pain—Prednisolone—psoriasis	2.85e-05	0.00025	CcSEcCtD
Omeprazole—Hepatitis—Methotrexate—psoriasis	2.85e-05	0.00025	CcSEcCtD
Omeprazole—Urticaria—Mycophenolate mofetil—psoriasis	2.84e-05	0.000249	CcSEcCtD
Omeprazole—Headache—Mycophenolic acid—psoriasis	2.84e-05	0.000249	CcSEcCtD
Omeprazole—Decreased appetite—Hydrocortisone—psoriasis	2.83e-05	0.000248	CcSEcCtD
Omeprazole—Pharyngitis—Methotrexate—psoriasis	2.83e-05	0.000248	CcSEcCtD
Omeprazole—Abdominal pain—Mycophenolate mofetil—psoriasis	2.82e-05	0.000248	CcSEcCtD
Omeprazole—Body temperature increased—Mycophenolate mofetil—psoriasis	2.82e-05	0.000248	CcSEcCtD
Omeprazole—Urinary tract disorder—Methotrexate—psoriasis	2.81e-05	0.000247	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.81e-05	0.000247	CcSEcCtD
Omeprazole—Fatigue—Hydrocortisone—psoriasis	2.81e-05	0.000246	CcSEcCtD
Omeprazole—CYP1B1—Metabolism—NDUFA5—psoriasis	2.8e-05	0.00118	CbGpPWpGaD
Omeprazole—Vision blurred—Prednisone—psoriasis	2.8e-05	0.000245	CcSEcCtD
Omeprazole—Urethral disorder—Methotrexate—psoriasis	2.79e-05	0.000245	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.79e-05	0.000245	CcSEcCtD
Omeprazole—Pain—Hydrocortisone—psoriasis	2.78e-05	0.000244	CcSEcCtD
Omeprazole—Anaphylactic shock—Betamethasone—psoriasis	2.78e-05	0.000244	CcSEcCtD
Omeprazole—Anaphylactic shock—Dexamethasone—psoriasis	2.78e-05	0.000244	CcSEcCtD
Omeprazole—Insomnia—Triamcinolone—psoriasis	2.77e-05	0.000243	CcSEcCtD
Omeprazole—Infection—Betamethasone—psoriasis	2.76e-05	0.000242	CcSEcCtD
Omeprazole—Infection—Dexamethasone—psoriasis	2.76e-05	0.000242	CcSEcCtD
Omeprazole—Ill-defined disorder—Prednisone—psoriasis	2.75e-05	0.000242	CcSEcCtD
Omeprazole—Paraesthesia—Triamcinolone—psoriasis	2.75e-05	0.000241	CcSEcCtD
Omeprazole—Feeling abnormal—Prednisolone—psoriasis	2.75e-05	0.000241	CcSEcCtD
Omeprazole—Visual impairment—Methotrexate—psoriasis	2.74e-05	0.000241	CcSEcCtD
Omeprazole—Anaemia—Prednisone—psoriasis	2.74e-05	0.000241	CcSEcCtD
Omeprazole—Shock—Dexamethasone—psoriasis	2.74e-05	0.00024	CcSEcCtD
Omeprazole—Shock—Betamethasone—psoriasis	2.74e-05	0.00024	CcSEcCtD
Omeprazole—Dyspnoea—Triamcinolone—psoriasis	2.73e-05	0.00024	CcSEcCtD
Omeprazole—Nervous system disorder—Betamethasone—psoriasis	2.73e-05	0.000239	CcSEcCtD
Omeprazole—Nervous system disorder—Dexamethasone—psoriasis	2.73e-05	0.000239	CcSEcCtD
Omeprazole—Agitation—Prednisone—psoriasis	2.73e-05	0.000239	CcSEcCtD
Omeprazole—Thrombocytopenia—Betamethasone—psoriasis	2.72e-05	0.000239	CcSEcCtD
Omeprazole—Thrombocytopenia—Dexamethasone—psoriasis	2.72e-05	0.000239	CcSEcCtD
Omeprazole—Tachycardia—Betamethasone—psoriasis	2.71e-05	0.000238	CcSEcCtD
Omeprazole—Tachycardia—Dexamethasone—psoriasis	2.71e-05	0.000238	CcSEcCtD
Omeprazole—Angioedema—Prednisone—psoriasis	2.71e-05	0.000238	CcSEcCtD
Omeprazole—Hypersensitivity—Cyclosporine—psoriasis	2.7e-05	0.000237	CcSEcCtD
Omeprazole—Dyspepsia—Triamcinolone—psoriasis	2.7e-05	0.000237	CcSEcCtD
Omeprazole—Erythema multiforme—Methotrexate—psoriasis	2.69e-05	0.000236	CcSEcCtD
Omeprazole—Nausea—Mycophenolic acid—psoriasis	2.69e-05	0.000236	CcSEcCtD
Omeprazole—Hyperhidrosis—Dexamethasone—psoriasis	2.69e-05	0.000236	CcSEcCtD
Omeprazole—Hyperhidrosis—Betamethasone—psoriasis	2.69e-05	0.000236	CcSEcCtD
Omeprazole—Feeling abnormal—Hydrocortisone—psoriasis	2.68e-05	0.000235	CcSEcCtD
Omeprazole—Malaise—Prednisone—psoriasis	2.68e-05	0.000235	CcSEcCtD
Omeprazole—Vertigo—Prednisone—psoriasis	2.67e-05	0.000234	CcSEcCtD
Omeprazole—Eye disorder—Methotrexate—psoriasis	2.66e-05	0.000234	CcSEcCtD
Omeprazole—Gastrointestinal pain—Hydrocortisone—psoriasis	2.66e-05	0.000234	CcSEcCtD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.66e-05	0.00112	CbGpPWpGaD
Omeprazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.66e-05	0.00112	CbGpPWpGaD
Omeprazole—Tinnitus—Methotrexate—psoriasis	2.66e-05	0.000233	CcSEcCtD
Omeprazole—Anorexia—Betamethasone—psoriasis	2.65e-05	0.000233	CcSEcCtD
Omeprazole—Anorexia—Dexamethasone—psoriasis	2.65e-05	0.000233	CcSEcCtD
Omeprazole—Urticaria—Prednisolone—psoriasis	2.65e-05	0.000232	CcSEcCtD
Omeprazole—Fatigue—Triamcinolone—psoriasis	2.64e-05	0.000232	CcSEcCtD
Omeprazole—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.63e-05	0.000231	CcSEcCtD
Omeprazole—Asthenia—Cyclosporine—psoriasis	2.63e-05	0.000231	CcSEcCtD
Omeprazole—Pain—Triamcinolone—psoriasis	2.62e-05	0.00023	CcSEcCtD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	2.62e-05	0.0011	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.61e-05	0.0011	CbGpPWpGaD
Omeprazole—Pruritus—Cyclosporine—psoriasis	2.59e-05	0.000227	CcSEcCtD
Omeprazole—Urticaria—Hydrocortisone—psoriasis	2.59e-05	0.000227	CcSEcCtD
Omeprazole—Immune system disorder—Methotrexate—psoriasis	2.57e-05	0.000226	CcSEcCtD
Omeprazole—Abdominal pain—Hydrocortisone—psoriasis	2.57e-05	0.000226	CcSEcCtD
Omeprazole—Body temperature increased—Hydrocortisone—psoriasis	2.57e-05	0.000226	CcSEcCtD
Omeprazole—Mediastinal disorder—Methotrexate—psoriasis	2.57e-05	0.000225	CcSEcCtD
Omeprazole—Asthenia—Mycophenolate mofetil—psoriasis	2.56e-05	0.000225	CcSEcCtD
Omeprazole—Hypertension—Prednisone—psoriasis	2.56e-05	0.000225	CcSEcCtD
Omeprazole—Chills—Methotrexate—psoriasis	2.56e-05	0.000224	CcSEcCtD
Omeprazole—ABCG2—Metabolism—NDUFA5—psoriasis	2.55e-05	0.00107	CbGpPWpGaD
Omeprazole—Musculoskeletal discomfort—Betamethasone—psoriasis	2.53e-05	0.000222	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.53e-05	0.000222	CcSEcCtD
Omeprazole—Pruritus—Mycophenolate mofetil—psoriasis	2.53e-05	0.000222	CcSEcCtD
Omeprazole—Myalgia—Prednisone—psoriasis	2.53e-05	0.000222	CcSEcCtD
Omeprazole—Arthralgia—Prednisone—psoriasis	2.53e-05	0.000222	CcSEcCtD
Omeprazole—Feeling abnormal—Triamcinolone—psoriasis	2.52e-05	0.000222	CcSEcCtD
Omeprazole—Anxiety—Prednisone—psoriasis	2.52e-05	0.000221	CcSEcCtD
Omeprazole—Alopecia—Methotrexate—psoriasis	2.52e-05	0.000221	CcSEcCtD
Omeprazole—Insomnia—Betamethasone—psoriasis	2.51e-05	0.000221	CcSEcCtD
Omeprazole—Insomnia—Dexamethasone—psoriasis	2.51e-05	0.000221	CcSEcCtD
Omeprazole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.51e-05	0.00022	CcSEcCtD
Omeprazole—Diarrhoea—Cyclosporine—psoriasis	2.51e-05	0.00022	CcSEcCtD
Omeprazole—Paraesthesia—Dexamethasone—psoriasis	2.5e-05	0.000219	CcSEcCtD
Omeprazole—Paraesthesia—Betamethasone—psoriasis	2.5e-05	0.000219	CcSEcCtD
Omeprazole—Discomfort—Prednisone—psoriasis	2.5e-05	0.000219	CcSEcCtD
Omeprazole—Mental disorder—Methotrexate—psoriasis	2.5e-05	0.000219	CcSEcCtD
Omeprazole—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	2.49e-05	0.00105	CbGpPWpGaD
Omeprazole—Malnutrition—Methotrexate—psoriasis	2.48e-05	0.000218	CcSEcCtD
Omeprazole—Hypersensitivity—Prednisolone—psoriasis	2.45e-05	0.000215	CcSEcCtD
Omeprazole—Dyspepsia—Betamethasone—psoriasis	2.45e-05	0.000215	CcSEcCtD
Omeprazole—Dyspepsia—Dexamethasone—psoriasis	2.45e-05	0.000215	CcSEcCtD
Omeprazole—Diarrhoea—Mycophenolate mofetil—psoriasis	2.44e-05	0.000214	CcSEcCtD
Omeprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	2.44e-05	0.00103	CbGpPWpGaD
Omeprazole—Urticaria—Triamcinolone—psoriasis	2.43e-05	0.000214	CcSEcCtD
Omeprazole—Dysgeusia—Methotrexate—psoriasis	2.43e-05	0.000213	CcSEcCtD
Omeprazole—Body temperature increased—Triamcinolone—psoriasis	2.42e-05	0.000213	CcSEcCtD
Omeprazole—Dizziness—Cyclosporine—psoriasis	2.42e-05	0.000212	CcSEcCtD
Omeprazole—Anaphylactic shock—Prednisone—psoriasis	2.42e-05	0.000212	CcSEcCtD
Omeprazole—Decreased appetite—Betamethasone—psoriasis	2.42e-05	0.000212	CcSEcCtD
Omeprazole—Decreased appetite—Dexamethasone—psoriasis	2.42e-05	0.000212	CcSEcCtD
Omeprazole—Infection—Prednisone—psoriasis	2.41e-05	0.000211	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Betamethasone—psoriasis	2.4e-05	0.000211	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Dexamethasone—psoriasis	2.4e-05	0.000211	CcSEcCtD
Omeprazole—Back pain—Methotrexate—psoriasis	2.4e-05	0.00021	CcSEcCtD
Omeprazole—Hypersensitivity—Hydrocortisone—psoriasis	2.4e-05	0.00021	CcSEcCtD
Omeprazole—Fatigue—Dexamethasone—psoriasis	2.4e-05	0.00021	CcSEcCtD
Omeprazole—Fatigue—Betamethasone—psoriasis	2.4e-05	0.00021	CcSEcCtD
Omeprazole—Shock—Prednisone—psoriasis	2.38e-05	0.000209	CcSEcCtD
Omeprazole—CYP1B1—Metabolism—CYP2S1—psoriasis	2.38e-05	0.001	CbGpPWpGaD
Omeprazole—Pain—Betamethasone—psoriasis	2.38e-05	0.000209	CcSEcCtD
Omeprazole—Pain—Dexamethasone—psoriasis	2.38e-05	0.000209	CcSEcCtD
Omeprazole—Nervous system disorder—Prednisone—psoriasis	2.37e-05	0.000208	CcSEcCtD
Omeprazole—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	2.37e-05	0.000996	CbGpPWpGaD
Omeprazole—Tachycardia—Prednisone—psoriasis	2.36e-05	0.000207	CcSEcCtD
Omeprazole—Dizziness—Mycophenolate mofetil—psoriasis	2.36e-05	0.000207	CcSEcCtD
Omeprazole—Skin disorder—Prednisone—psoriasis	2.35e-05	0.000206	CcSEcCtD
Omeprazole—Hyperhidrosis—Prednisone—psoriasis	2.34e-05	0.000205	CcSEcCtD
Omeprazole—Vision blurred—Methotrexate—psoriasis	2.34e-05	0.000205	CcSEcCtD
Omeprazole—Asthenia—Hydrocortisone—psoriasis	2.33e-05	0.000205	CcSEcCtD
Omeprazole—Vomiting—Cyclosporine—psoriasis	2.33e-05	0.000204	CcSEcCtD
Omeprazole—Rash—Cyclosporine—psoriasis	2.31e-05	0.000203	CcSEcCtD
Omeprazole—Anorexia—Prednisone—psoriasis	2.31e-05	0.000203	CcSEcCtD
Omeprazole—Dermatitis—Cyclosporine—psoriasis	2.31e-05	0.000202	CcSEcCtD
Omeprazole—Pruritus—Hydrocortisone—psoriasis	2.3e-05	0.000202	CcSEcCtD
Omeprazole—Ill-defined disorder—Methotrexate—psoriasis	2.3e-05	0.000202	CcSEcCtD
Omeprazole—Headache—Cyclosporine—psoriasis	2.29e-05	0.000201	CcSEcCtD
Omeprazole—Anaemia—Methotrexate—psoriasis	2.29e-05	0.000201	CcSEcCtD
Omeprazole—Feeling abnormal—Dexamethasone—psoriasis	2.29e-05	0.000201	CcSEcCtD
Omeprazole—Feeling abnormal—Betamethasone—psoriasis	2.29e-05	0.000201	CcSEcCtD
Omeprazole—Gastrointestinal pain—Dexamethasone—psoriasis	2.27e-05	0.0002	CcSEcCtD
Omeprazole—Gastrointestinal pain—Betamethasone—psoriasis	2.27e-05	0.0002	CcSEcCtD
Omeprazole—Vomiting—Mycophenolate mofetil—psoriasis	2.27e-05	0.000199	CcSEcCtD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.26e-05	0.000952	CbGpPWpGaD
Omeprazole—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	2.26e-05	0.00095	CbGpPWpGaD
Omeprazole—Hypersensitivity—Triamcinolone—psoriasis	2.26e-05	0.000198	CcSEcCtD
Omeprazole—Rash—Mycophenolate mofetil—psoriasis	2.25e-05	0.000198	CcSEcCtD
Omeprazole—Dermatitis—Mycophenolate mofetil—psoriasis	2.25e-05	0.000197	CcSEcCtD
Omeprazole—Headache—Mycophenolate mofetil—psoriasis	2.24e-05	0.000196	CcSEcCtD
Omeprazole—Malaise—Methotrexate—psoriasis	2.24e-05	0.000196	CcSEcCtD
Omeprazole—Vertigo—Methotrexate—psoriasis	2.23e-05	0.000195	CcSEcCtD
Omeprazole—Diarrhoea—Hydrocortisone—psoriasis	2.23e-05	0.000195	CcSEcCtD
Omeprazole—Leukopenia—Methotrexate—psoriasis	2.22e-05	0.000195	CcSEcCtD
Omeprazole—Urticaria—Dexamethasone—psoriasis	2.21e-05	0.000194	CcSEcCtD
Omeprazole—Urticaria—Betamethasone—psoriasis	2.21e-05	0.000194	CcSEcCtD
Omeprazole—Musculoskeletal discomfort—Prednisone—psoriasis	2.21e-05	0.000194	CcSEcCtD
Omeprazole—Dizziness—Prednisolone—psoriasis	2.2e-05	0.000193	CcSEcCtD
Omeprazole—Asthenia—Triamcinolone—psoriasis	2.2e-05	0.000193	CcSEcCtD
Omeprazole—Body temperature increased—Betamethasone—psoriasis	2.2e-05	0.000193	CcSEcCtD
Omeprazole—Abdominal pain—Betamethasone—psoriasis	2.2e-05	0.000193	CcSEcCtD
Omeprazole—Body temperature increased—Dexamethasone—psoriasis	2.2e-05	0.000193	CcSEcCtD
Omeprazole—Abdominal pain—Dexamethasone—psoriasis	2.2e-05	0.000193	CcSEcCtD
Omeprazole—Insomnia—Prednisone—psoriasis	2.19e-05	0.000192	CcSEcCtD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.18e-05	0.000917	CbGpPWpGaD
Omeprazole—Nausea—Cyclosporine—psoriasis	2.17e-05	0.000191	CcSEcCtD
Omeprazole—Paraesthesia—Prednisone—psoriasis	2.17e-05	0.000191	CcSEcCtD
Omeprazole—Pruritus—Triamcinolone—psoriasis	2.17e-05	0.00019	CcSEcCtD
Omeprazole—ABCG2—Metabolism—CYP2S1—psoriasis	2.17e-05	0.000911	CbGpPWpGaD
Omeprazole—Cough—Methotrexate—psoriasis	2.16e-05	0.00019	CcSEcCtD
Omeprazole—Dizziness—Hydrocortisone—psoriasis	2.15e-05	0.000189	CcSEcCtD
Omeprazole—Dyspepsia—Prednisone—psoriasis	2.13e-05	0.000187	CcSEcCtD
Omeprazole—ABCB1—Allograft Rejection—IFNG—psoriasis	2.13e-05	0.000895	CbGpPWpGaD
Omeprazole—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.12e-05	0.000894	CbGpPWpGaD
Omeprazole—Nausea—Mycophenolate mofetil—psoriasis	2.12e-05	0.000186	CcSEcCtD
Omeprazole—Arthralgia—Methotrexate—psoriasis	2.11e-05	0.000185	CcSEcCtD
Omeprazole—Myalgia—Methotrexate—psoriasis	2.11e-05	0.000185	CcSEcCtD
Omeprazole—Chest pain—Methotrexate—psoriasis	2.11e-05	0.000185	CcSEcCtD
Omeprazole—Decreased appetite—Prednisone—psoriasis	2.1e-05	0.000185	CcSEcCtD
Omeprazole—Rash—Prednisolone—psoriasis	2.1e-05	0.000184	CcSEcCtD
Omeprazole—Dermatitis—Prednisolone—psoriasis	2.1e-05	0.000184	CcSEcCtD
Omeprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.1e-05	0.000184	CcSEcCtD
Omeprazole—Fatigue—Prednisone—psoriasis	2.09e-05	0.000183	CcSEcCtD
Omeprazole—Headache—Prednisolone—psoriasis	2.09e-05	0.000183	CcSEcCtD
Omeprazole—Discomfort—Methotrexate—psoriasis	2.09e-05	0.000183	CcSEcCtD
Omeprazole—Constipation—Prednisone—psoriasis	2.07e-05	0.000182	CcSEcCtD
Omeprazole—Vomiting—Hydrocortisone—psoriasis	2.07e-05	0.000182	CcSEcCtD
Omeprazole—Rash—Hydrocortisone—psoriasis	2.05e-05	0.00018	CcSEcCtD
Omeprazole—Dermatitis—Hydrocortisone—psoriasis	2.05e-05	0.00018	CcSEcCtD
Omeprazole—Confusional state—Methotrexate—psoriasis	2.04e-05	0.000179	CcSEcCtD
Omeprazole—Headache—Hydrocortisone—psoriasis	2.04e-05	0.000179	CcSEcCtD
Omeprazole—Dizziness—Triamcinolone—psoriasis	2.03e-05	0.000178	CcSEcCtD
Omeprazole—Anaphylactic shock—Methotrexate—psoriasis	2.02e-05	0.000178	CcSEcCtD
Omeprazole—Infection—Methotrexate—psoriasis	2.01e-05	0.000176	CcSEcCtD
Omeprazole—Feeling abnormal—Prednisone—psoriasis	2e-05	0.000175	CcSEcCtD
Omeprazole—Asthenia—Betamethasone—psoriasis	1.99e-05	0.000175	CcSEcCtD
Omeprazole—Asthenia—Dexamethasone—psoriasis	1.99e-05	0.000175	CcSEcCtD
Omeprazole—Nervous system disorder—Methotrexate—psoriasis	1.98e-05	0.000174	CcSEcCtD
Omeprazole—Thrombocytopenia—Methotrexate—psoriasis	1.98e-05	0.000174	CcSEcCtD
Omeprazole—Gastrointestinal pain—Prednisone—psoriasis	1.98e-05	0.000174	CcSEcCtD
Omeprazole—Nausea—Prednisolone—psoriasis	1.98e-05	0.000174	CcSEcCtD
Omeprazole—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.98e-05	0.000832	CbGpPWpGaD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	1.98e-05	0.000832	CbGpPWpGaD
Omeprazole—Pruritus—Betamethasone—psoriasis	1.97e-05	0.000173	CcSEcCtD
Omeprazole—Pruritus—Dexamethasone—psoriasis	1.97e-05	0.000173	CcSEcCtD
Omeprazole—Skin disorder—Methotrexate—psoriasis	1.97e-05	0.000172	CcSEcCtD
Omeprazole—Hyperhidrosis—Methotrexate—psoriasis	1.96e-05	0.000172	CcSEcCtD
Omeprazole—CYP11A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.96e-05	0.000823	CbGpPWpGaD
Omeprazole—Vomiting—Triamcinolone—psoriasis	1.95e-05	0.000171	CcSEcCtD
Omeprazole—Nausea—Hydrocortisone—psoriasis	1.93e-05	0.00017	CcSEcCtD
Omeprazole—Rash—Triamcinolone—psoriasis	1.93e-05	0.00017	CcSEcCtD
Omeprazole—Dermatitis—Triamcinolone—psoriasis	1.93e-05	0.000169	CcSEcCtD
Omeprazole—Anorexia—Methotrexate—psoriasis	1.93e-05	0.000169	CcSEcCtD
Omeprazole—Urticaria—Prednisone—psoriasis	1.92e-05	0.000169	CcSEcCtD
Omeprazole—Headache—Triamcinolone—psoriasis	1.92e-05	0.000168	CcSEcCtD
Omeprazole—Body temperature increased—Prednisone—psoriasis	1.91e-05	0.000168	CcSEcCtD
Omeprazole—Abdominal pain—Prednisone—psoriasis	1.91e-05	0.000168	CcSEcCtD
Omeprazole—Diarrhoea—Betamethasone—psoriasis	1.9e-05	0.000167	CcSEcCtD
Omeprazole—Diarrhoea—Dexamethasone—psoriasis	1.9e-05	0.000167	CcSEcCtD
Omeprazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.86e-05	0.000781	CbGpPWpGaD
Omeprazole—Musculoskeletal discomfort—Methotrexate—psoriasis	1.84e-05	0.000162	CcSEcCtD
Omeprazole—Dizziness—Betamethasone—psoriasis	1.84e-05	0.000161	CcSEcCtD
Omeprazole—Dizziness—Dexamethasone—psoriasis	1.84e-05	0.000161	CcSEcCtD
Omeprazole—Insomnia—Methotrexate—psoriasis	1.83e-05	0.000161	CcSEcCtD
Omeprazole—CYP11A1—Metabolism—CARM1—psoriasis	1.82e-05	0.000767	CbGpPWpGaD
Omeprazole—Nausea—Triamcinolone—psoriasis	1.82e-05	0.00016	CcSEcCtD
Omeprazole—Paraesthesia—Methotrexate—psoriasis	1.82e-05	0.000159	CcSEcCtD
Omeprazole—Dyspnoea—Methotrexate—psoriasis	1.8e-05	0.000158	CcSEcCtD
Omeprazole—Somnolence—Methotrexate—psoriasis	1.8e-05	0.000158	CcSEcCtD
Omeprazole—Hypersensitivity—Prednisone—psoriasis	1.78e-05	0.000157	CcSEcCtD
Omeprazole—Dyspepsia—Methotrexate—psoriasis	1.78e-05	0.000156	CcSEcCtD
Omeprazole—Vomiting—Dexamethasone—psoriasis	1.77e-05	0.000155	CcSEcCtD
Omeprazole—Vomiting—Betamethasone—psoriasis	1.77e-05	0.000155	CcSEcCtD
Omeprazole—Decreased appetite—Methotrexate—psoriasis	1.76e-05	0.000154	CcSEcCtD
Omeprazole—Rash—Betamethasone—psoriasis	1.75e-05	0.000154	CcSEcCtD
Omeprazole—Rash—Dexamethasone—psoriasis	1.75e-05	0.000154	CcSEcCtD
Omeprazole—Dermatitis—Betamethasone—psoriasis	1.75e-05	0.000154	CcSEcCtD
Omeprazole—Dermatitis—Dexamethasone—psoriasis	1.75e-05	0.000154	CcSEcCtD
Omeprazole—Gastrointestinal disorder—Methotrexate—psoriasis	1.75e-05	0.000153	CcSEcCtD
Omeprazole—Fatigue—Methotrexate—psoriasis	1.74e-05	0.000153	CcSEcCtD
Omeprazole—Headache—Betamethasone—psoriasis	1.74e-05	0.000153	CcSEcCtD
Omeprazole—Headache—Dexamethasone—psoriasis	1.74e-05	0.000153	CcSEcCtD
Omeprazole—Asthenia—Prednisone—psoriasis	1.74e-05	0.000152	CcSEcCtD
Omeprazole—Pain—Methotrexate—psoriasis	1.73e-05	0.000152	CcSEcCtD
Omeprazole—CYP1A1—Metabolism—NDUFA5—psoriasis	1.72e-05	0.000725	CbGpPWpGaD
Omeprazole—Pruritus—Prednisone—psoriasis	1.71e-05	0.00015	CcSEcCtD
Omeprazole—CYP11A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.7e-05	0.000717	CbGpPWpGaD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.69e-05	0.000713	CbGpPWpGaD
Omeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.69e-05	0.000713	CbGpPWpGaD
Omeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	1.68e-05	0.000707	CbGpPWpGaD
Omeprazole—Feeling abnormal—Methotrexate—psoriasis	1.67e-05	0.000146	CcSEcCtD
Omeprazole—Diarrhoea—Prednisone—psoriasis	1.66e-05	0.000145	CcSEcCtD
Omeprazole—Gastrointestinal pain—Methotrexate—psoriasis	1.65e-05	0.000145	CcSEcCtD
Omeprazole—Nausea—Betamethasone—psoriasis	1.65e-05	0.000145	CcSEcCtD
Omeprazole—Nausea—Dexamethasone—psoriasis	1.65e-05	0.000145	CcSEcCtD
Omeprazole—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.65e-05	0.000692	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.63e-05	0.000686	CbGpPWpGaD
Omeprazole—Urticaria—Methotrexate—psoriasis	1.61e-05	0.000141	CcSEcCtD
Omeprazole—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.61e-05	0.000676	CbGpPWpGaD
Omeprazole—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.61e-05	0.000676	CbGpPWpGaD
Omeprazole—Dizziness—Prednisone—psoriasis	1.6e-05	0.000141	CcSEcCtD
Omeprazole—Abdominal pain—Methotrexate—psoriasis	1.6e-05	0.00014	CcSEcCtD
Omeprazole—Body temperature increased—Methotrexate—psoriasis	1.6e-05	0.00014	CcSEcCtD
Omeprazole—CYP2C8—Metabolism—NDUFA5—psoriasis	1.58e-05	0.000665	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—CARM1—psoriasis	1.58e-05	0.000663	CbGpPWpGaD
Omeprazole—Vomiting—Prednisone—psoriasis	1.54e-05	0.000135	CcSEcCtD
Omeprazole—ABCC3—Metabolism—CARM1—psoriasis	1.53e-05	0.000645	CbGpPWpGaD
Omeprazole—Rash—Prednisone—psoriasis	1.53e-05	0.000134	CcSEcCtD
Omeprazole—Dermatitis—Prednisone—psoriasis	1.53e-05	0.000134	CcSEcCtD
Omeprazole—Headache—Prednisone—psoriasis	1.52e-05	0.000133	CcSEcCtD
Omeprazole—Hypersensitivity—Methotrexate—psoriasis	1.49e-05	0.000131	CcSEcCtD
Omeprazole—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.47e-05	0.00062	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—CYP2S1—psoriasis	1.47e-05	0.000617	CbGpPWpGaD
Omeprazole—Asthenia—Methotrexate—psoriasis	1.45e-05	0.000127	CcSEcCtD
Omeprazole—Nausea—Prednisone—psoriasis	1.44e-05	0.000126	CcSEcCtD
Omeprazole—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.43e-05	0.000603	CbGpPWpGaD
Omeprazole—Pruritus—Methotrexate—psoriasis	1.43e-05	0.000126	CcSEcCtD
Omeprazole—CYP2C19—Metabolism—NDUFA5—psoriasis	1.41e-05	0.000593	CbGpPWpGaD
Omeprazole—Diarrhoea—Methotrexate—psoriasis	1.38e-05	0.000122	CcSEcCtD
Omeprazole—ABCB1—Allograft Rejection—TNF—psoriasis	1.38e-05	0.000579	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—NDUFA5—psoriasis	1.38e-05	0.000579	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.37e-05	0.000576	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—CYP2S1—psoriasis	1.34e-05	0.000565	CbGpPWpGaD
Omeprazole—Dizziness—Methotrexate—psoriasis	1.34e-05	0.000117	CcSEcCtD
Omeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.32e-05	0.000553	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—NDUFA5—psoriasis	1.3e-05	0.000546	CbGpPWpGaD
Omeprazole—Vomiting—Methotrexate—psoriasis	1.29e-05	0.000113	CcSEcCtD
Omeprazole—CYP2C9—Metabolism—NDUFA5—psoriasis	1.29e-05	0.000541	CbGpPWpGaD
Omeprazole—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.28e-05	0.000538	CbGpPWpGaD
Omeprazole—Rash—Methotrexate—psoriasis	1.28e-05	0.000112	CcSEcCtD
Omeprazole—Dermatitis—Methotrexate—psoriasis	1.27e-05	0.000112	CcSEcCtD
Omeprazole—Headache—Methotrexate—psoriasis	1.27e-05	0.000111	CcSEcCtD
Omeprazole—CYP1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.25e-05	0.000525	CbGpPWpGaD
Omeprazole—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.22e-05	0.000514	CbGpPWpGaD
Omeprazole—Nausea—Methotrexate—psoriasis	1.2e-05	0.000105	CcSEcCtD
Omeprazole—CYP2C19—Metabolism—CYP2S1—psoriasis	1.2e-05	0.000505	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.2e-05	0.000505	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—CYP2S1—psoriasis	1.17e-05	0.000493	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—CARM1—psoriasis	1.16e-05	0.000489	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—CAT—psoriasis	1.12e-05	0.000472	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—CYP2S1—psoriasis	1.1e-05	0.000464	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—NDUFA5—psoriasis	1.1e-05	0.000462	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—CYP2S1—psoriasis	1.09e-05	0.00046	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.09e-05	0.000457	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—CARM1—psoriasis	1.06e-05	0.000445	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.02e-05	0.000431	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—CAT—psoriasis	9.7e-06	0.000408	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—CAT—psoriasis	9.43e-06	0.000397	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—CYP2S1—psoriasis	9.35e-06	0.000393	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	9.08e-06	0.000382	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.74e-06	0.000368	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—APOE—psoriasis	8.71e-06	0.000366	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—NDUFA5—psoriasis	8.48e-06	0.000357	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.93e-06	0.000334	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.68e-06	0.000323	CbGpPWpGaD
Omeprazole—CYP11A1—Metabolism—PPARG—psoriasis	7.58e-06	0.000319	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—APOE—psoriasis	7.53e-06	0.000317	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—APOE—psoriasis	7.33e-06	0.000308	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—CYP2S1—psoriasis	7.21e-06	0.000303	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—CARM1—psoriasis	7.16e-06	0.000301	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—CAT—psoriasis	7.15e-06	0.000301	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.04e-06	0.000296	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.8e-06	0.000286	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.69e-06	0.000281	CbGpPWpGaD
Omeprazole—CYP2C18—Metabolism—PPARG—psoriasis	6.56e-06	0.000276	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—CARM1—psoriasis	6.56e-06	0.000276	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—CAT—psoriasis	6.5e-06	0.000274	CbGpPWpGaD
Omeprazole—ABCC3—Metabolism—PPARG—psoriasis	6.38e-06	0.000269	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.29e-06	0.000264	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.13e-06	0.000258	CbGpPWpGaD
Omeprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.99e-06	0.000252	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—CARM1—psoriasis	5.86e-06	0.000246	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.73e-06	0.000241	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—CARM1—psoriasis	5.72e-06	0.000241	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—APOE—psoriasis	5.55e-06	0.000234	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.47e-06	0.00023	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—CARM1—psoriasis	5.39e-06	0.000227	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—CARM1—psoriasis	5.34e-06	0.000225	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—APOE—psoriasis	5.05e-06	0.000213	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.99e-06	0.00021	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.9e-06	0.000206	CbGpPWpGaD
Omeprazole—CYP1B1—Metabolism—PPARG—psoriasis	4.84e-06	0.000204	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—CARM1—psoriasis	4.56e-06	0.000192	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—CAT—psoriasis	4.4e-06	0.000185	CbGpPWpGaD
Omeprazole—ABCG2—Metabolism—PPARG—psoriasis	4.4e-06	0.000185	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.27e-06	0.000179	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—CAT—psoriasis	4.04e-06	0.00017	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—CAT—psoriasis	3.6e-06	0.000152	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—CARM1—psoriasis	3.52e-06	0.000148	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—CAT—psoriasis	3.52e-06	0.000148	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—APOE—psoriasis	3.42e-06	0.000144	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—CAT—psoriasis	3.31e-06	0.000139	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—CAT—psoriasis	3.29e-06	0.000138	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—APOE—psoriasis	3.14e-06	0.000132	CbGpPWpGaD
Omeprazole—CYP1A1—Metabolism—PPARG—psoriasis	2.98e-06	0.000125	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—CAT—psoriasis	2.81e-06	0.000118	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—APOE—psoriasis	2.8e-06	0.000118	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—APOE—psoriasis	2.73e-06	0.000115	CbGpPWpGaD
Omeprazole—CYP2C8—Metabolism—PPARG—psoriasis	2.73e-06	0.000115	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—APOE—psoriasis	2.57e-06	0.000108	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—APOE—psoriasis	2.55e-06	0.000107	CbGpPWpGaD
Omeprazole—CYP2C19—Metabolism—PPARG—psoriasis	2.44e-06	0.000103	CbGpPWpGaD
Omeprazole—ABCB1—Metabolism—PPARG—psoriasis	2.38e-06	0.0001	CbGpPWpGaD
Omeprazole—CYP2D6—Metabolism—PPARG—psoriasis	2.24e-06	9.44e-05	CbGpPWpGaD
Omeprazole—CYP2C9—Metabolism—PPARG—psoriasis	2.22e-06	9.35e-05	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—APOE—psoriasis	2.18e-06	9.18e-05	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—CAT—psoriasis	2.17e-06	9.11e-05	CbGpPWpGaD
Omeprazole—CYP1A2—Metabolism—PPARG—psoriasis	1.9e-06	7.99e-05	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—APOE—psoriasis	1.68e-06	7.08e-05	CbGpPWpGaD
Omeprazole—CYP3A4—Metabolism—PPARG—psoriasis	1.47e-06	6.17e-05	CbGpPWpGaD
